scholarly journals Secondary lymphoma development after chemotherapy in three dogs

Author(s):  
Jeong Mi Kim ◽  
Hong Jae Yi ◽  
Kun Ho Song ◽  
Kyoung Won Seo
Keyword(s):  
Author(s):  
Selman Ünal ◽  
Halil Uzundal ◽  
Turker Soydaş ◽  
Asım Özayar ◽  
Arslan Ardıçoğlu ◽  
...  

Primary or secondary lymphoma of the prostate is a rare condition. Mantle cell lymphoma (MCL) represent 4-9% of all lymphomas. Prostate involvement with MCL is very rare, with only 11 reported cases up to now. Here we present a case with lower urinary tract symptoms and prostate-specific antigen (PSA) elevation diagnosed with MCL of the prostate. Prostate biopsy was performed in a 70-year-old patient due to increased PSA. After the pathology result was reported as prostatic MCL, imaging studies and sampling of additional pathological specimens were performed for staging. An improvement was observed in the urinary system complaints of the patient who started chemotherapy regimen. While prostatectomy was performed in some of the prostatic MCL cases reported previously, in some, no additional treatment was required after chemotherapy. Our case is the only prostatic MCL case with elevated PSA levels, but did not receive the diagnosis of prostate cancer. Physicians should keep in mind that, prostatic MCL can present with nonspecific symptoms. Staging should be performed in patients whose histopathologic diagnosis is lymphoma of the prostate so as to determine appropriate treatment options.


2013 ◽  
Vol 92 (2) ◽  
pp. 63-63
Author(s):  
Lorraine Williams-Smith ◽  
Reena Gupta ◽  
Ryan F. Osborne

Lymphoma accounts for 15% of malignant salivary gland tumors. The parotid gland is the most commonly affected salivary gland (80%). It is generally seen in older men and women. It is associated with human immunodeficiency virus (HIV) infection and in approximately 6% of patients with Sjogrin's syndrome. There are two types: Hodgkin lymphoma and Non-Hodgkin lymphoma. Parotid lymphoma may be primary or secondary (far more common). Primary lymphoma first involves the parotid gland and later other parts of the body including lymph nodes and bone marrow. Secondary lymphoma involves other parts of the body first, such as peripheral blood, lymph nodes, bone marrow, and other organs. Treatment depends upon stage, overall health, age, and subtype of lymphoma. It includes chemotherapy, total or radical parotidectomy, and radiotherapy. If there is no response, or the chance of recurrence is high, then bone marrow transplantation or stem cell transplantation can be considered.


Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6073
Author(s):  
Anna Nydegger ◽  
Urban Novak ◽  
Marie-Noëlle Kronig ◽  
Myriam Legros ◽  
Sacha Zeerleder ◽  
...  

(1) Background: CAR-T-cell therapy is a novel therapeutic option for patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The parameters that predict a favorable outcome after CAR-T-cell treatment are a matter of ongoing exploration. (2) Methods: We analyzed 36 consecutive patients with r/r DLBCL receiving tisagenlecleucel or axicabtagene ciloleucel at a single academic institution. We hypothesized that lymphoma subtypes (transformed versus de novo DLBCL) are of prognostic importance. We also assessed age, previous treatment, bridging therapy, remission status at the time of CAR-T treatment and at six months, LDH, the occurrence of CRS or ICANS, and CAR-T-DNA ddPCR kinetics for their prognostic impact. (3) Results: CRS was observed in 24 (67%) patients, and ICANS was observed in 14 (39%) patients. CR was achieved in 20 (56%) patients. Achievement of CR within six months after CAR-T was associated with better PFS (p < 0.0001) and OS (p < 0.0001). Remarkably, transformed (=secondary) lymphoma was associated with a better outcome than de novo disease for PFS (p = 0.0093) and OS (p = 0.0209), and the CR rate was 78% versus 33% (p = 0.0176). Mortality in patients with transformed DLBCL was 23% compared with 56% in de novo patients (p = 0.0209). (4) Conclusion: The presence of transformed DLBCL seems to be associated with a more favorable course after CAR-T treatment than that observed in the de novo DLBCL patients.


1985 ◽  
Vol 17 (1) ◽  
pp. 29-34 ◽  
Author(s):  
Surabhi Kakati ◽  
Jerzy R. Kowalczyk ◽  
Reinhard Becher ◽  
Avery A. Sandberg
Keyword(s):  

2019 ◽  
Vol 7 (12) ◽  
pp. 1492-1498
Author(s):  
Sen Han ◽  
Tao An ◽  
Wei-Ping Liu ◽  
Yu-Qin Song ◽  
Jun Zhu

Sign in / Sign up

Export Citation Format

Share Document